ReviewJournal of clinical medicine2025
All You Need to Know About TACE: A Comprehensive Review of Indications, Techniques, Efficacy, Limits, and Technical Advancement.
Review in Journal of clinical medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed.
- Efficacy of lenvatinib combined with sintilimab and transcatheter arterial chemoembolization in conversion therapy for unresectable hepatocellular carcinoma.Pakistan journal of medical sciences · 2026Article
- Interventional Embolization Under Multifactorial Coupling: Mechanisms of Embolic-Agent Distribution and Feasibility of Closed-Loop Automatic Injection.Annals of biomedical engineering · 2026Review
- Drug-eluting bead transarterial chemoembolization treatment of liver-dominant metastatic leiomyosarcoma.Abdominal radiology (New York) · 2026Article
- High-sensitivity photoelectric sensing of apatinib for recurrent hepatocellular carcinoma in TACE.RSC advances · 2026Article
- Review
- Review
- NLR-based nomogram predicts survival in hepatocellular carcinoma treated with TACE plus targeted immunotherapy.BMC cancer · 2026Article
- Review
- The State of the Art in Combination Locoregional and Systemic Treatment Strategies for Hepatocellular Carcinoma: Recent Advancements and Future Horizons.Current oncology (Toronto, Ont.) · 2026Review
- Clinical outcomes of carbon-ion radiotherapy for residual or recurrent hepatocellular carcinoma after transarterial chemoembolization.ESMO gastrointestinal oncology · 2026Article
- Retrospective Italian Registry on DSM-TACE: Experience Beyond Current Recommendations.Cancers · 2026Article
- Advances in the Therapeutic Landscape of Hepatocellular Carcinoma: Current Strategies and Future Perspectives.Cancers · 2026Review
- Retrospective Analysis of the Clinical Efficacy, Safety, and Influencing Factors of Drug-Eluting Bead Transarterial Chemoembolization for Unresectable Hepatic Malignancies.Clinical Medicine Insights. Oncology · 2026Article
- Perceived benefits and barriers to health behaviors after transarterial chemoembolization in patients with hepatocellular carcinoma: a qualitative study based on the health belief model.Frontiers in medicine · 2026Article
- Management of hepatocellular carcinoma prior to liver transplantation: latest developments.Hepatic oncology · 2025Review
- Intra-arterial lidocaine improves long-term survival in patients with hepatocellular carcinoma undergoing transcatheter arterial chemoembolisation. Comment on Br J Anaesth 2025; 134: 1628-37.British journal of anaesthesia · 2025Article
- Selective Angiographic Roadmap Analysis (SARA) of Hepatocellular Carcinoma Feeding Arteries for Transarterial Chemoembolization.Diagnostics (Basel, Switzerland) · 2025Review
- Review
- Endoscopic management of pancreatic and biliary duct stenoses due to a giant pseudoaneurysm in a patient clinically suggestive of Loeys-Dietz syndrome.Clinical journal of gastroenterology · 2025Article
- Locoregional Therapies for Hepatocellular Carcinoma with Portal Vein Tumor Thrombus.Journal of gastrointestinal cancer · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Transcatheter arterial chemoembolization (TACE) is a proven and widely accepted treatment option for hepatocellular carcinoma and it is recommended as first-line non-curative therapy for BCLC B/intermediate HCC (preserved liver function, multifocal, no cancer-related symptoms) in patients without vascular involvement. Different types of TACE are available nowadays, including TAE, c-TACE, DEB-TACE, and DSM-TACE, but at present there is insufficient evidence to recommend one TACE technique over another and the choice is left to the operator. This review then aims to provide a comprehensive overview of the current literature on indications, types of procedures, safety, and efficacy of different TACE treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.